在服用治疗良性前列腺增生症药物的男性患者中,出现复发性缺血性中风的风险增加
Chun-Gu Cheng1,2, Chun-Fang Chen3, Wu-Chien Chien4,5
1Department of Emergency Medicine, Taoyuan Armed Forces General Hospital, Taoyuan 32549, Taiwan.
Life (Basel, Switzerland)
|February 27, 2026
概括
良性前列腺增生 (BPH) 增加了复发性缺血性中风 (IS) 的风险. 治疗BPH的药物,包括α-1阻断剂和高剂量的5α减少酶抑制剂,与中风患者复发性IS的风险较高有关.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 良性前列腺增生 (BPH) 与心血管疾病风险增加有关.
- 用于BPH的α-1阻塞剂与主要的不良心血管事件有关.
- 缺血性中风 (IS) 患者可能会由于自主功能障碍而经历大脑自身调节受损.
研究的目的:
- 调查良性前列腺增生症 (BPH) 药物治疗与复发性缺血性中风 (IS) 风险之间的关联.
主要方法:
- 使用台湾国家医疗保险数据库 (2000-2015年) 进行的回顾性队列研究.
- 确定了新诊断的缺血性中风 (IS) 和良性前列腺增生 (BPH) 的患者.
- 使用考克斯的比例危险回归,评估与经常性IS相关的因素.
主要成果:
- 良性前列腺增生 (BPH) 与复发性IS的风险增加1.505倍相关 (aHR: 1.505,95% CI: 1.112-1.829).
- 阿尔法-1 阻断剂治疗显示,复发性IS的风险增加了 1.581 倍 (aHR: 1.581,95% CI: 1.16-1.915).
- 长期使用高剂量的5α减少酶抑制剂也与复发性IS的风险增加有关.
结论:
- 研究结果表明,良性前列腺增生 (BPH) 与复发性缺血性中风 (IS) 风险之间存在显著的关联.
- 在有史以来缺血性中风 (IS) 的患者中,建议对BPH的药物治疗保持谨慎.
相关概念视频
Disorders of the Male Reproductive System
5.2K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.2K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
663
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
663
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
316
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
552
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
552
Antianginal Drugs: Nitrates and β-Blockers
1.8K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.8K
Antihypertensive Drugs: Vasodilators
2.3K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.3K


